{"product_id":"international-textbook-of-diabetes-mellitus-2-volume-set-isbn-9780470658611","title":"International Textbook of Diabetes Mellitus, 2 Volume Set","description":"\u003cp\u003eThe \u003ci\u003eInternational Textbook of Diabetes Mellitus\u003c\/i\u003e has been a successful, well-respected medical textbook for almost 20 years, over 3 editions. Encyclopaedic and international in scope, the textbook covers all aspects of diabetes ensuring a truly multidisciplinary and global approach. Sections covered include epidemiology, diagnosis, pathogenesis, management and complications of diabetes and public health issues worldwide. It incorporates a vast amount of new data regarding the scientific understanding and clinical management of this disease, with each new edition always reflecting the substantial advances in the field. Whereas other diabetes textbooks are primarily clinical with less focus on the basic science behind diabetes, \u003ci\u003eITDM's\u003c\/i\u003e primary philosophy has always been to comprehensively cover the basic science of metabolism, linking this closely to the pathophysiology and clinical aspects of the disease.\u003c\/p\u003e \u003cp\u003eEdited by four world-famous diabetes specialists, the book is divided into 13 sections, each section edited by a section editor of major international prominence. As well as covering all aspects of diabetes, from epidemiology and pathophysiology to the management of the condition and the complications that arise, this fourth edition also includes two new sections on NAFLD, NASH and non-traditional associations with diabetes, and clinical trial evidence in diabetes.\u003c\/p\u003e \u003cp\u003eThis fourth edition of an internationally recognised textbook will once again provide all those involved in diabetes research and development, as well as diabetes specialists with the most comprehensive scientific reference book on diabetes available.\u003c\/p\u003e \u003cp\u003eContributors xi\u003c\/p\u003e \u003cp\u003ePreface xxiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection I: Epidemiology\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Classification of diabetes mellitus and other categories of glucose intolerance 3\u003cbr\u003e\u003ci\u003eDianna J. Magliano, Paul Zimmet and Jonathan E. Shaw\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Epidemiology and risk factors for type 1 diabetes mellitus 17\u003cbr\u003e\u003ci\u003eAndrea K. Steck and Marian J. Rewers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Epidemiology and geography of type 2 diabetes mellitus 29\u003cbr\u003e\u003ci\u003eQing Qiao, Desmond E.Williams, Giuseppina Imperatore, K.M. Venkat Narayan and Jaakko Tuomilehto\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection II: Physiology of pancreatic function\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e4 Development and maintenance of the islet β cell 55\u003cbr\u003e\u003ci\u003eTeresa L. Mastracci, Raghavendra G. Mirmira and Ryan M. Anderson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Pancreatic morphology in normal and diabetic states 69\u003cbr\u003e\u003ci\u003eRebecca L. Hull and Steven E. Kahn\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Insulin gene expression and biosynthesis 82\u003cbr\u003e\u003ci\u003eVincent Poitout, Roland Stein and Christopher J. Rhodes\u003c\/i\u003e\u003cbr\u003e\u003cbr\u003e7 β-Cell biology of insulin secretion 96\u003cbr\u003e\u003ci\u003eSusumu Seino, Tadao Shibasaki and Kohtaro Minami\u003c\/i\u003e\u003cbr\u003e\u003cbr\u003e8 Normal β-cell function 108\u003cbr\u003e\u003ci\u003eAndrea Natali, Stefano Del Prato and Andrea Mari\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Neuropeptides and islet hormone secretion 125\u003cbr\u003e\u003ci\u003eBo Ahrén\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Biosynthesis secretion and action of glucagon 136\u003cbr\u003e\u003ci\u003ePierre J. Lefèbvre\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Incretin physiology in health and disease 145\u003cbr\u003e\u003ci\u003eJuris J. Meier and Michael A. Nauck\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection III: Normal physiology of insulin action\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12 Mechanisms of insulin signal transduction 163\u003cbr\u003e\u003ci\u003ePaul R. Langlais, Lawrence J. Mandarino and W. Timothy Garvey\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Regulation of glucose metabolism in liver 193\u003cbr\u003e\u003ci\u003eShawn C. Burgess\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Insulin actions in vivo: glucose metabolism 211\u003cbr\u003e\u003ci\u003eEle Ferrannini and Ralph A. DeFronzo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Measuring insulin action in vivo 234\u003cbr\u003e\u003ci\u003eRichard N. Bergman and Marilyn Ader\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Protein metabolism in health and diabetes 250\u003cbr\u003e\u003ci\u003eElena Volpi and Jared M. Dickinson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Lipid and lipoprotein metabolism hypolipidemic agents and therapeutic goals 262\u003cbr\u003e\u003ci\u003eGissette Reyes-Soffer and Henry N. Ginsberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Metabolomics: applications in type 2 diabetes mellitus and insulin resistance 275\u003cbr\u003e\u003ci\u003eSean H. Adams and John W. Newman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection IV: NAFLD NASH and non-traditional associations with diabetes\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e19 Pathogenesis of nonalcoholic fatty liver disease (NAFLD) 283\u003cbr\u003e\u003ci\u003eHannele Yki-Järvinen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) 292\u003cbr\u003e\u003ci\u003eFernando Bril, Kwame Ntim, Romina Lomonaco and Kenneth Cusi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Type 2 diabetes and cancer 306\u003cbr\u003e\u003ci\u003eEmily Jane Gallagher, Ruslan Novosyadlyy and Derek LeRoith\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Diabetes and sleep apnea 316\u003cbr\u003e\u003ci\u003eAbd A. Tahrani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection V: Pathogenesis\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e23 The insulin resistance syndrome 339\u003cbr\u003e\u003ci\u003eNaveed Sattar, Paul Welsh and David Preiss\u003c\/i\u003e\u003cbr\u003e\u003cbr\u003e24 β-Cell mass and function in human type 2 diabetes 354\u003cbr\u003e\u003ci\u003ePiero Marchetti and Ele Ferrannini\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Pathogenesis of type 2 diabetes mellitus 371\u003cbr\u003e\u003ci\u003eRalph A. DeFronzo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 The genetics of type 2 diabetes 401\u003cbr\u003e\u003ci\u003eEmma Ahlqvist and Leif Groop\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Glucose toxicity 413\u003cbr\u003e\u003ci\u003eHannele Yki-Järvinen and Donald A. McClain\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Monogenic disorders of the β cell 426\u003cbr\u003e\u003ci\u003eAli J. Chakera and Andrew T. Hattersley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Immunopathogenesis of type 1 diabetes in Western society 442\u003cbr\u003e\u003ci\u003eAlberto Pugliese\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Molecular genetics of type 1 diabetes 454\u003cbr\u003e\u003ci\u003eM. Ann Kelly, Simon D. Rees, Anthony H. Barnett and Stephen C. Bain\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection VI: Obesity\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e31 The relationship between obesity and type 2 diabetes—the role of gut factors 469\u003cbr\u003e\u003ci\u003eDaniel S. Hsia and William T. Cefalu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 The role of energy metabolism in the regulation of energy balance 479\u003cbr\u003e\u003ci\u003eCharmaine S. Tam and Eric Ravussin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Treatment of obesity: lifestyle and pharmacotherapy 489\u003cbr\u003e\u003ci\u003eArne Astrup\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Treatment of obesity: bariatric surgery 505\u003cbr\u003e\u003ci\u003eKarl J. Neff Ele Ferrannini and Carel W. le Roux\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 Animal models of obesity and type 2 diabetes 519\u003cbr\u003e\u003ci\u003eDavid A. York, Mie Jung, Park-York and Timothy Gilbertson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 The role of the hypothalamus in themaintenance of energy balance and peripheral glucose control 529\u003cbr\u003e\u003ci\u003eLuis Varela and Tamas L. Horvath\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection VII: Clinical trial evidence in diabetes\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e37 Prevention of type 1 diabetes 541\u003cbr\u003e\u003ci\u003eJay S. Skyler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e38 Prevention of type 2 diabetes 550\u003cbr\u003e\u003ci\u003eThomas Yates and Melanie J. Davies\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e39 Prevention of diabetic microvascular complications 564\u003cbr\u003e\u003ci\u003eAlice P.S. Kong and Juliana C.N. Chan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection VIII: Management of diabetes: diet exercise and drugs\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e40 Dietary management of diabetes mellitus in Europe and North America 577\u003cbr\u003e\u003ci\u003eJim I. Mann and Alexandra Chisholm\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e41 Exercise 589\u003cbr\u003e\u003ci\u003eHenrik Galbo and Erik A. Richter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e42 Sulfonylureas and meglitinides: insights into physiology and translational clinical utility 615\u003cbr\u003e\u003ci\u003eHarold E. Lebovitz and Arne Melander\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e43 Metformin and other biguanides: pharmacology and therapeutic usage 641\u003cbr\u003e\u003ci\u003eSusan L. Samson and Alan J. Garber\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e44 PPAR agonists in the treatment of diabetes 657\u003cbr\u003e\u003ci\u003eSunder Mudaliar and Robert R. Henry\u003c\/i\u003e\u003cbr\u003e\u003cbr\u003e45 α-Glucosidase inhibitors 673\u003cbr\u003e\u003ci\u003eJosée Leroux-Stewart, Rémi Rabasa-Lhoret and Jean-Louis Chiasson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e46 Combination therapy in type 2 diabetes mellitus 686\u003cbr\u003e\u003ci\u003eMuhammad Abdul-Ghani, Ralph A. DeFronzo and Roy Eldor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e47 New drugs for the treatment of diabetes mellitus 709\u003cbr\u003e\u003ci\u003eClifford J. Bailey\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e48 Incretin-based therapies 726\u003cbr\u003e\u003ci\u003eMichael A. Nauck and Juris J. Meier\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e49 Insulin pumps 745\u003cbr\u003e\u003ci\u003eDace L. Trence and Irl B. Hirsch\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e50 Innovative therapies in diabetes: colesevelam and bromocriptine 758\u003cbr\u003e\u003ci\u003eShamsa Ali and Vivian Fonseca\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection IX: Management of diabetes: monitoring and other interventions\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e51 Implantable pumps and artificial and bio-artificial pancreas system 767\u003cbr\u003e\u003ci\u003eWilliam V. Tamborlane and Miladys M. Palau-Collazo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e52 Pancreas and islet transplantation 774\u003cbr\u003e\u003ci\u003eR. Paul Robertson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e53 Hypoglycemia and other complications of insulin therapy 783\u003cbr\u003e\u003ci\u003eStephanie A. Amiel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e54 Diabetic ketoacidosis and hyperosmolar state 799\u003cbr\u003e\u003ci\u003eAbbas E. Kitabchi, Guillermo E. Umpierrez and Mary Beth Murphy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection X: Management of diabetes: glucose and lipid monitoring specific subgroups\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e55 Type 2 diabetes in obese adolescents: pathophysiology and treatment 817\u003cbr\u003e\u003ci\u003eGrace Kim and Sonia Caprio\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e56 Diabetes in pregnancy 823\u003cbr\u003e\u003ci\u003eYoel Toledano, Eran Hadar and Moshe Hod\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e57 Aging and diabetes mellitus 836\u003cbr\u003e\u003ci\u003eHermes Florez, Jorge Ruiz and Medha Munshi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e58 Psychological problems and management of patients with diabetes mellitus 846\u003cbr\u003e\u003ci\u003eAlan M. Delamater, Ashley Marchante, and Jennifer Hernandez\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e59 Glycated hemoglobin serum proteins and other markers as tools for monitoring 853\u003cbr\u003e\u003ci\u003eSusan M. Gerber, Douglas F. Stickle, Intekhab Ahmed, and Serge A. Jabbour\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection XI: Complications of diabetes: general and microvasular\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e60 Pathogenesis of diabetic microvascular complications 875\u003cbr\u003e\u003ci\u003eJosephine M. Forbes and Brooke Harcourt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e61 Diabetic retinopathy and other ocular complications 889\u003cbr\u003e\u003ci\u003eGavin S. Tan and Tien YinWong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e62 Diabetic nephropathy 911\u003cbr\u003e\u003ci\u003eGeorge Jerums, Elif I. Ekinci, Erosha Premaratne, Scott T. Baker, Sianna Panagiotopoulos and Richard J. MacIsaac\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e63 Pathology of human diabetic neuropathy 926\u003cbr\u003e\u003ci\u003eM. Mojaddidi, A.K. Sharma and Rayaz A. Malik\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e64 Autonomic neuropathy 939\u003cbr\u003e\u003ci\u003eChinmay S. Marathe, Liza Phillips and Michael Horowitz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e65 Connective tissue disorders in diabetes 953\u003cbr\u003e\u003ci\u003eArlan L. Rosenbloom\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e66 The diabetic foot 964\u003cbr\u003e\u003ci\u003eFrank L. Bowling and Andrew J.M. Boulton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e67 Erectile dysfunction in diabetes mellitus 975\u003cbr\u003e\u003ci\u003eMichael H. Cummings and Rajesh Rajendran\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e68 Periodontal disease and diabetes mellitus 988\u003cbr\u003e\u003ci\u003eWenche S. Borgnakke and Robert J. Genco\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection XII: Complications of diabetes: macrovascular\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e69 Epidemiology of macrovascular disease and hypertension in diabetes mellitus 1007\u003cbr\u003e\u003ci\u003eJaakko Tuomilehto, Daiva Rastenyte, Qing Qiao, Noël C. Barengo and Karl Matz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e70 Atherogenesis coronary heart disease and insulin resistance syndrome in diabetes 1031\u003cbr\u003e\u003ci\u003eBarak Zafrir and Jorge Plutzky\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e71 Endothelial function and metabolic syndrome 1046\u003cbr\u003e\u003ci\u003eXinpu Chen and Sridevi Devaraj\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e72 Hemostatic abnormalities in diabetes mellitus 1051\u003cbr\u003e\u003ci\u003eR.A. Ajjan and Peter J. Grant\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e73 Clinical features and treatment of coronary heart disease in diabetes 1064\u003cbr\u003e\u003ci\u003eEberhard Standl, Michael Erbach, Markolf Hanefeld, Oliver Schnell, Bernd Stratmann and Diethelm Tschoepe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e74 Arterial hypertension in diabetes: etiology and treatment 1079\u003cbr\u003e\u003ci\u003eColleen Flynn and George Bakris\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e75 Peripheral vascular and cerebrovascular disease in diabetes mellitus 1091\u003cbr\u003e\u003ci\u003eDebabrata Mukherjee\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection XIII: Diabetes and public health\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e76 The diabetes challenge: from human and social rights to the empowerment of people with diabetes 1105\u003cbr\u003e\u003ci\u003eC.T. Di Iorio, Fabrizio Carinci and M. Massi Benedetti\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e77 The economics of diabetes care: a global perspective 1113\u003cbr\u003e\u003ci\u003eRhys Williams\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex i\u003c\/p\u003e \u003cp\u003e\u003cb\u003eRalph DeFronzo, \u003c\/b\u003eProfessor of Medicine and Chief of the Diabetes Division, \u003cbr\u003eThe University of Texas Health Science Centre at San Antonio, and Deputy Director of Texas Diabetic Institute, San Antonio, Texas, USA.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eEle Ferrannini, \u003c\/b\u003eProfessor of Internal Medicine, Department of Clinical and Experimental Medicine, University of Pisa School of Medicine, Pisa, Italy.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eK. George M. M Alberti\u003c\/b\u003e, Visiting Professor, King's College, London, UK; Senior Research Investigator, Imperial College, London, UK; Emeritus Professor of Medicine, University of Newcastle upon Tyne, Newcastle upon Tyne.\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePaul Zimmet\u003c\/b\u003e, Director Emeritus, Victor Smorgon Diabetes Centre, Baker IDI Heart and Diabetes Institute; Adjunct Professor, Monash University; Honorary President, International Diabetes Federation; Chair, Programme Committee, World Diabetes Congress 2013, Melbourne, VIC, Australia.\u003c\/p\u003e \u003cp\u003eThe \u003ci\u003eInternational Textbook of Diabetes Mellitus \u003c\/i\u003ehas been a successful, well-respected medical textbook for almost 20 years, over 3 editions. Encyclopaedic and international in scope, the textbook covers all aspects of diabetes ensuring a truly multidisciplinary and global approach. Sections covered include epidemiology, diagnosis, pathogenesis, management and complications of diabetes and public health issues worldwide. It incorporates a vast amount of new data regarding the scientific understanding and clinical management of this disease, with each new edition always reflecting the substantial advances in the field. Whereas other diabetes textbooks are primarily clinical with less focus on the basic science behind diabetes, \u003ci\u003eITDM's\u003c\/i\u003e primary philosophy has always been to comprehensively cover the basic science of metabolism, linking this closely to the pathophysiology and clinical aspects of the disease.\u003c\/p\u003e \u003cp\u003eEdited by four world-famous diabetes specialists, the book is divided into 13 sections, each section edited by a section editor of major international prominence. As well as covering all aspects of diabetes, from epidemiology and pathophysiology to the management of the condition and the complications that arise, this fourth edition also includes two new sections on NAFLD, NASH and non-traditional associations with diabetes, and clinical trial evidence in diabetes.\u003c\/p\u003e \u003cp\u003eThis fourth edition of an internationally recognised textbook will once again provide all those involved in diabetes research and development, as well as diabetes specialists with the most comprehensive scientific reference book on diabetes available.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989450244325,"sku":"NP9780470658611","price":428.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470658611.jpg?v=1761784147","url":"https:\/\/k12savings.com\/es\/products\/international-textbook-of-diabetes-mellitus-2-volume-set-isbn-9780470658611","provider":"K12savings","version":"1.0","type":"link"}